A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers

Kaifeng Liu,Meijia Li,Yudong Li,Yutong Li,Zixin Chen,Yiqi Tang,Meitian Yang,Guoquan Deng,Hongwei Liu
DOI: https://doi.org/10.1186/s12943-024-01963-7
IF: 37.3
2024-03-25
Molecular Cancer
Abstract:While strategies such as chemotherapy and immunotherapy have become the first-line standard therapies for patients with advanced or metastatic cancer, acquired resistance is still inevitable in most cases. The introduction of antibody‒drug conjugates (ADCs) provides a novel alternative. ADCs are a new class of anticancer drugs comprising the coupling of antitumor mAbs with cytotoxic drugs. Compared with chemotherapeutic drugs, ADCs have the advantages of good tolerance, accurate target recognition, and small effects on noncancerous cells. ADCs occupy an increasingly important position in the therapeutic field. Currently, there are 13 Food and Drug Administration (FDA)‒approved ADCs and more than 100 ADC drugs at different stages of clinical trials. This review briefly describes the efficacy and safety of FDA-approved ADCs, and discusses the related problems and challenges to provide a reference for clinical work.
oncology,biochemistry & molecular biology
What problem does this paper attempt to address?
The paper attempts to address the issue of exploring the clinical efficacy and safety of antibody-drug conjugates (ADCs) in the treatment of human cancers. Specifically, the paper reviews the efficacy and safety of 13 ADCs approved by the U.S. Food and Drug Administration (FDA) and discusses related challenges and issues, providing references for clinical applications and scientific research. ### Main Content: 1. **Background**: - Cancer has become the second largest health threat globally, causing approximately 10 million deaths annually. - Traditional anti-tumor therapies such as chemotherapy and radiotherapy have many drawbacks. - Antibody-drug conjugates (ADCs), as a new type of anti-cancer drug, have better safety and efficacy. 2. **Structure and Mechanism of ADCs**: - ADCs consist of three parts: humanized monoclonal antibodies (mAbs), linkers, and cytotoxic drugs. - mAbs recognize antigens on the target cell membrane and enter the cell through endocytosis. - Inside the cell, ADCs are degraded in the acidic environment and by proteases, releasing cytotoxic drugs that lead to cell cycle arrest and apoptosis. 3. **Approved ADCs and Their Applications**: - The paper details 13 FDA-approved ADCs, including their targets, antibody types, linkers, and cytotoxic drugs. - For example, Gemtuzumab Ozogamicin (GO) is used to treat acute myeloid leukemia (AML), Brentuximab Vedotin (BV) is used to treat Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL), and Trastuzumab Emtansine (T-DM1) is used to treat HER2-positive breast cancer, among others. 4. **Clinical Efficacy and Safety**: - The paper summarizes the clinical trial results of these ADCs in different cancers, including objective response rate (ORR), complete response rate (CR), event-free survival (EFS), overall survival (OS), and other indicators. - Additionally, the paper discusses the safety issues of these ADCs, such as the incidence and severity of adverse events (AEs). 5. **Challenges and Future Directions**: - The paper points out some challenges faced by ADCs in clinical applications, such as drug resistance and management of toxic side effects. - It proposes future research directions, including optimizing the design of ADCs, improving targeting, and reducing toxic side effects. ### Conclusion: By reviewing and analyzing the clinical data of approved ADCs, this paper provides valuable references for clinicians and researchers, helping to better understand and apply this new type of anti-cancer drug.